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Abstract
Background: Rett syndrome (RTT) is a complex neurological disorder that is one of the most frequent causes of mental
retardation in women. A great landmark in research in this field was the discovery of a relationship between the disease and
the presence of mutations in the gene that codes for the methyl-CpG binding protein 2 (MeCP2). Currently, MeCP2 is
thought to act as a transcriptional repressor that couples DNA methylation and transcriptional silencing. The present study
aimed to identify new target genes regulated by Mecp2 in a mouse model of RTT.
Methodology/Principal Findings: We have compared the gene expression profiles of wild type (WT) and Mecp2-null (KO)
mice in three regions of the brain (cortex, midbrain, and cerebellum) by using cDNA microarrays. The results obtained were
confirmed by quantitative real-time PCR. Subsequent chromatin immunoprecipitation assays revealed seven direct target
genes of Mecp2 bound in vivo (Fkbp5, Mobp, Plagl1, Ddc, Mllt2h, Eya2, and S100a9), and three overexpressed genes due to
an indirect effect of a lack of Mecp2 (Irak1, Prodh and Dlk1). The regions bound by Mecp2 were always methylated,
suggesting the involvement of the methyl-CpG binding domain of the protein in the mechanism of interaction.
Conclusions: We identified new genes that are overexpressed in Mecp2-KO mice and are excellent candidate genes for
involvement in various features of the neurological disease. Our results demonstrate new targets of MeCP2 and provide us
with a better understanding of the underlying mechanisms of RTT.
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Introduction
Rett syndrome (RTT, OMIM 312750) is a complex and severe
neurological disease. This X-linked disorder is the second most
frequent cause of mental retardation in women, affecting one out
of every 10,000–15,000 live births. After apparently normal
development for 6–18 months, RTT girls lose their acquired
cognitive, social, and motor skills [1], and develop autistic
behavior accompanied by stereotypic hand movements. Further
deterioration leads to severe mental retardation and motor
impairments, including ataxia, apraxia, and tremors. Seizures,
hyperventilation, and apnea are also common [2]. Male RTT
patients have also been described; they usually suffer a more severe
progression.
The development of this syndrome has been related to
mutations in the gene encoding methyl-CpG-binding protein 2
(MeCP2) [3]. The MECP2 gene is located on Xq28 and consists of
four exons spanning a region more than 75 kb long [4,5]. Two
isoforms of MeCP2 have been described to date [6,7].
DNA methylation of specific sites in CpG islands is an
important epigenetic mechanism in the regulation of some genes.
Proteins with an affinity for methyl-CpGs, such as MeCP2,
provide a link between DNA methylation and chromatin
remodeling [8–11]. Moreover, there is growing evidence of a
multifunctional role of MeCP2 [12] that is in accordance with its
four different functional domains: (1) a methyl-CpG-binding
domain (MBD), which accounts for MeCP2-specific binding to
methyl-CpG pairs [13]; (2) an arginine-glycine repeat RNA-
binding domain [14]; (3) a transcriptional repression domain
(TRD) that interacts with a corepressor complex involving
mSin3A and histone deacetylases [15]; and (4) an RNA splicing
factor binding region (WW group II binding domain) [16].
In the first studies of MeCP2, abundant binding sites of this
protein were found in genomic chromatin, and MeCP2 seemed
capable of long-range repression [17]. Later it was involved in
large-scale reorganization of pericentromeric heterochromatin
during differentiation [18]. Although some reports initially
suggested that MeCP2 action strongly influenced gene expression
levels, more detailed analyses showed only subtle differences in
expression patterns between wild type and MeCP2-deficient
samples [19]. Despite the identification of a diverse set of target
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genes for MeCP2 [8,20,21], it remains unclear how MeCP2
dysfunction ultimately results in the neuronal syndrome. A very
recent and surprising breakthrough in the field has been provided
by Chahrour and co-workers [22], where the authors studied gene
expression patterns in the hypothalamus of mice that either lack or
overexpress MECP2 and observed that a majority of genes
appeared to be activated by MeCP2. Thus, this study suggests that
MeCP2 can function as an activator and a repressor of
transcription [22].
Although Mecp2 is expressed in a wide range of tissues, the
major features of RTT have already been reported as being
mainly caused by the neuronal deficiency of Mecp2 [23], and for
this reason we confined our study to the central nervous system
(CNS). Given the difficulties of working with human samples, we
chose a well-established mouse model of RTT that mimics the
human disease [24]. The purpose of our study was to identify new
target genes of Mecp2 in neuronal tissue from a mouse model of
RTT, starting from an expression microarray approach and
proceding with the validation of the target genes by single
expression, chromatin immunoprecipitation and DNA methyla-
tion analyses. Using this strategy, we have unmasked previously
uncharacterized genes that are disregulated in CNS upon Mecp2
disruption.
Results
Expression profile
In order to identify genes specifically regulated by Mecp2, we
first carried out an expression-profile experiment in three separate
brain regions (cortex, midbrain, and cerebellum), in an attempt to
determine whether there was a brain region that was more
sensitive to the lack of Mecp2 or that showed different regulation
patterns. Total RNA was isolated from brain sections obtained
from Mecp2-null (KO) mice and their wild type (WT) littermates.
We performed direct competitive hybridization between WT and
KO tissues, comparing each brain region separately. Four
biological replicates were made, providing a total of twelve
microarrays.
First, an ANOVA (analysis of variance) showed no significant
differences between brain regions (ANOVA, adjusted p,0.05),
indicating that CNS gene expression was homogeneous (with
respect to the divisions made), thereby justifying the combined
analysis of all the microarrays. Despite the sensitivity of the
experiments and the large number of replicates, the significance
analysis of microarrays [25] did not reveal any genes that were
differentially expressed with respect to the false discovery rate
(FDR). Although we found no significant differences, the
microarrays yielded a list of genes whose expression was very
likely to be affected by the lack of Mecp2. Globally there were few
genes whose expression changed by .1.5-fold. Only 29 probes
were upregulated in KO mice (two genes with at least twice the
level of expression) (Table 1), and 24 downregulated (two genes
with less than half the level of expression) (Table 2). The fact that
Mecp2 was as the most downregulated gene in KO mice confirmed
that the experiments were reliable (Table 2).
Given that Mecp2 is known to be a transcriptional repressor
and we were looking for direct targets of the protein, we focused
our work on the genes that appeared to be upregulated in KO
mice (Fig. 1). Moreover, we decided to study further those
candidate genes from the microarray data that had been
associated with neuronal function in published studies or that
could be connected with Mecp2 function for their association with
imprinting or X-chromosome inactivation. With that criterion we
followed our study working with 20 genes, pointed by an arrow in
Table 1. The second most down-regulated gene (Gprasp1) was
chosen as a control gene for following assays (Mecp2 was not
appropriate as it was missing from KO mice) (Table 2).
Validation of expression changes
We first checked that the mouse model was working
appropriately by testing the expression of the two Mecp2 isoforms
described to date [7,26]. Neither isoform could be detected in
brain tissue from the KO mice, while the WT mice showed
normal expression (Fig. 2 and Table 3), confirming that the model
worked in accordance with our expectations.
To validate the microarray results, we performed quantitative
real-time PCR (qRT-PCR) of all the previously selected genes. We
reverse-transcribed total RNA from all brain regions of three KO
mice and their corresponding WT littermates. After normalizing
the data with respect to their own Gapdh results, the expression
values of all genes in the WT and KO mice were compared among
the three brain regions separately. Statistical analysis (Welch’s t
test) of these data provided the p-values shown in Table 3.
Ten of the 20 upregulated genes tested were confirmed to be
consistently upregulated in at least two of the three brain tissues by
qRT-PCR. Eight genes (Fkbp5, Irak1, Mobp, Dlk1, Plagl1, Ddc,
Mllt2h, and Eya2) had significantly stronger expression in KO mice
in all the tissues studied. Additionally, two other genes (Prodh and
S100a9) had a significantly higher level in two of the brain areas
(cortex/cerebellum and cortex/midbrain, respectively) (Table 3).
Given that severe symptoms of the RTT syndrom (anxiety,
autonomic abnormalities, sleep-wake rhythm…) could be attri-
buted to hypothalamic dysfunction and that this brain region
undergo important gene expression changes upon Mecp2
impairment [22], we assessed the expression of our observed
Mecp2-null mice upregulated genes in the hypothalamus. We
found that these genes (Fkbp5, Ddc, Dlk1, Irak1, Mllt2h, Mobp,
Plagl1, Eya2, ProDH and S100a9) where also all of them identified as
upregulated in the hypothalamus of our MeCP2-null mice (Figure
S1). To add internal methodological consistency to these data, we
confirmed that those genes previously found downregulated in the
hypothalamus upon Mecp2 disruption (such as Sst, Gamt, Creb1
and Oprk1) [22] were also found downregulated in the
hypothalamus of our Mecp2 null mice (Figure S2). We also
observed that Sst, Gamt, Creb1 and Oprk1 were downregulated in
the cortex, midbrain and cerebellum of our Mecp2 null mice
(Figure S2). The five most downregulated genes of our microarray
study (Gprasp1, Sc4mol, Calb1, Fabp7 and Itm2a) were also
significantly more weakly expressed in all the brain tissues studied
in the Mecp2 null mice (Table 3 and Figure S3). Fkbp5 has already
been identified as an upregulated gene in the mouse model of Rett
Syndrome [27] so can be considered as a positive control of the
accuracy and appropriateness of the experiments.
It is remarkable that the expression of some genes (Fkbp5, Irak1,
Dlk1, Ddc, andMllt2h) in KO mice is twice that of the levels in WT
mice, while the level of expression of other genes (Mobp, Prodh,
Plagl1, Eya2, and S100a9) was 40–50% higher than those of WT
values. Conversely, one of the overexpressed genes, Dlk1, is
transcriptionally regulated by the methylation status of the CpGs
upstream of Gtl2 gene [28–30]. For this reason we tested Gtl2
expression and confirmed that it did not change in KO mice with
respect to WT levels (data not shown). Subsequent studies were
made only with genes whose differences in levels of expression
were confirmed by these assays (Fig. 1).
Mecp2 direct binding to gene promoters
Having completed the expression experiments, we wondered
which genes were directly regulated by Mecp2. To reveal whether
Mecp2 Targets in Rett
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Mecp2 interacts with the gene promoters, we carried out
conventional chromatin immunoprecipitation (ChIP) and quanti-
tative-Chip (qChIP) assays. We tested the promoter regions of the
genes confirmed by qRT-PCR and found that seven of the ten
upregulated genes were bound to their promoter region by Mecp2
(Fkbp5, Mobp, Plagl1, Ddc, Mllt2h, Eya2, and S100a9) (Fig. 3 and
Figure S4). However, although the region close to the Dlk1
transcriptional start site was not bound by Mecp2, this gene has
been described as being regulated by the region upstream Glt2
[28–30]. Therefore, to confirm possible regulation by Mecp2, we
checked the region upstream of Gtl2 and found that it was bound
by Mecp2 (Fig. 3 and Figure S4). For the downregulated genes
Gprasp1, Sc4mol, Calb1, Fabp7 and Itm2a (Fig. 3 and Figure S3), we
did not observe Mecp2 occupancy in their corresponding 59-
regulatory regions (Figure S3).
Conversely, we also found two genes, Irak1 and Prodh, whose
expression was indirectly affected by the lack of Mecp2, because
this protein did not interact with their promoter regions (Fig. 3 and
Figure S4).
DNA methylation analysis of particular genes
As Mecp2 is a methyl-CpG binding protein, we decided to
explore the methylation status of gene promoters overlapping the
Mecp2-bound regions. We extracted DNA from the three different
brain regions of WT and KO mice and performed bisulfite
sequencing (BS) analyzing ten clones for each condition. Statistical
analyses of the resulting percentages of methylation showed no
strong evidence of differences between the brain regions studied
(ANOVA –see Methods–, p = 0.076). Moreover, there were no
modifications in the DNA methylation pattern between WT and
KO mice (ANOVA –see Methods–, p = 0.688), as Mecp2 has not
been proposed to alter DNA methylation. BS results from one
representative sample of each gene are shown in Fig. 4. From the
ten confirmed upregulated genes, seven were methylated promot-
ers, corresponding to Fkbp5, Mobp, Plagl1, Ddc, Mllt2h, Eya2, and
S100a9. While Dlk1 promoter was unmethylated, the CpGs
upstream Gtl2 (corresponding to the Mecp2-bound region) was
methylated, which implies that this region is responsible for Mecp2
regulation of Dlk1 expression. For the imprinted genes Plagl, Ddc
Table 1. Probes with higher level of expression in KO samples than in WT controls. (upregulated), as determined by microarray
analysis.
Name UniGene GeneBank Description n-fold change
c Fkbp5 Mm.276405 BG087373 FK506 binding protein 5 2.76 b
c Mt1 Mm.192991 BG077818 Metallothionein 1 2.25 b
c Bai1 Mm.43133 BC037726 Brain-specific angiogenesis inhibitor 1 1.99 b
c Mt2 Mm.147226 BG063925 Metallothionein 2 1.94 b
c Pcolce2 Mm.46016 BQ561584 Procollagen C-endopeptidase enhancer 2 1.90 b
Pnpla2 Mm.29998 BG077619 Patatin-like phospholipase domain containing 2 1.73
Rpl36 Mm.379094 BG072993 Sulfatase modifying factor 1 1.72
c Irak1 Mm.38241 BG076768 Interleukin-1 receptor-associated kinase 1 1.71 b
c Mobp Mm.40461 AK013799 Myelin-associated oligodendrocytic basic protein 1.62 b
BQ550269 1.58
c Prodh Mm.28456 BQ553283 Proline dehydrogenase 1.55 b
c Dlk1 Mm.157069 BQ550065 Delta-like 1 homolog (Drosophila) 1.55 b
Rps15 Mm.643 BG088213 Ribosomal protein S15 1.55
c Plagl1 Mm.287857 BG085853 Pleiomorphic adenoma gene-like 1 1.54 b
c Ddc Mm.12906 BQ554377 Dopa decarboxylase 1.52 b
c Gas5 Mm.270065 BG085421 Growth arrest specific 5 1.52 b
c Mllt2h Mm.6949 BQ554269 AF4/FMR2 family, member 1 1.52 b
AW555131 1.52
c Txnip Mm.271877 BG086605 Thioredoxin interacting protein 1.52 b
c Eya2 Mm.282719 BG069346 Eyes absent 2 homolog (Drosophila) 1.51 b
c Cpm Mm.339332 BQ560184 Carboxypeptidase M 1.51 b
c Nudt9 Mm.241484 BQ561264 Nudix (nucleoside diphosphate linked moiety X)-type motif 9 1.51 b
1700084E18Rik Mm.297949 BG070023 RIKEN cDNA 1700084E18 gene 1.50
1700023B02Rik Mm.292140 BG065239 RIKEN cDNA 1700023B02 gene 1.50
c Pxmp2 Mm.21853 BG086336 Peroxisomal membrane protein 2 1.50 b
2010315L10Rik Mm.41890 BG063434 RIKEN cDNA 2010315L10 gene 1.50
Rpl18a Mm.379251 BG072556 Ribosomal protein L18A 1.50
c Ucp2 Mm.171378 BG087187 Uncoupling protein 2 (mitochondrial, proton carrier) 1.50 b
c S100a9 Mm.2128 BG072801 S100 calcium binding protein A9 (calgranulin B) 1.50 b
Only probes with .1.5-fold change are shown.
Genes selected for subsequent assays are in bold and indicated by arrows (c b).
doi:10.1371/journal.pone.0003669.t001
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and Gtl2, an extended analysis of twenty clones from bisulfite
genomic sequencing rendered approximately a 50% unmethylated
/ 50% methylated sequences, as expected (Figure S5). In the end,
all the gene promoters that were directly bound by Mecp2 were
methylated, whilst the 59-ends of Irak1 and ProDH (where Mecp2
was not bound) were unmethylated (Figure 4). In comparison, the
five downregulated genes identified upon Mecp2 disruption
(Gprasp1, Sc4mol, Calb1, Fabp7 and Itm2a) were all of them
unmethylated, in concordance with the results recently described
by Chahrourt et al. [22]
Discussion
The purpose of this study was to identify new direct target genes
of Mecp2 that could explain the development of RTT. To address
this matter we first compared the RNA expression patterns of KO
mice and their WT littermates using an expression microarray
approach. We analyzed three brain regions but the microarray
results did not show gene expression differences between the
tissues. Nevertheless the expression profile comparisons highlight-
ed a group of genes with altered expression in KO mice that
exceeded a 1.5-fold change threshold. Consistent with previous
reports [19,20,31] only a few genes showed a difference in
expression in the absence of Mecp2, which is one of the most
striking features of RTT.
We concentrated our study on genes that were upregulated in
KO mice, given that our purpose was to find direct target genes of
the transcriptional repressor Mecp2. Focusing our study on genes
that could be relevant to RTT, qRT-PCR validated ten genes as
being consistently upregulated in KO mouse brains. Subsequent
ChIP assays showed that three of these genes (Irak1, Dlk1 and
Prodh) were upregulated, probably due to an indirect effect of the
lack of Mecp2. On the other hand, we found that seven of the
consistently upregulated genes (Fkbp5, Mobp, Plagl1, Ddc, Mllt2h,
Eya2, and S100a9) were directly bound by Mecp2 to their
promoter or regulatory region (Fig. 1).
The use of BS to characterize the DNA regions bound by
Mecp2 revealed no methylation differences between brain regions
or between KO and WT samples, so the expression differences
were a direct consequence of the absence of Mecp2. Moreover, the
regions bound by Mecp2 were always methylated, suggesting that
the regulation carried out by Mecp2 might involve the MBD
domain of the protein. It is not well known how the absence of
Mecp2 would give rise to an increased expression at the DNA-
methylated genes, but a loss of Mecp2-mediated recruitment of
other partners of the chromatin and epigenetic machinery (such as
histone deacetylases and histone methyltransferases) might be
involved. In this regard, depletion of Mecp2 in human cancer cells
by RNA interference is also able to partially induce release of gene
silencing of DNA methylated CpG islands in association with a
Table 2. Probes with lower level of expression in KO samples than in WT controls (downregulated), as determined by microarray
analysis.
Name UniGene GeneBank Description n-fold change
Sqle Mm.296169 BG077950 Squalene epoxidase 0.67
Rock1 Mm.6710 BG088815 Rho-associated coiled-coil forming kinase 1 0.67
BG067593 0.67
Scd2 Mm.193096 BG066641 Stearoyl-Coenzyme A desaturase 2 0.66
5031439A09Rik Mm.369129 BQ559666 RIKEN cDNA 5031439A09 gene 0.66
Eif4g2 Mm.185453 BG070960 Eukaryotic translation initiation factor 4, gamma 2 0.66
c Calb1 Mm.277665 BG071405 Calbindin-28K 0.66 b
Taf5l Mm.291777 CK335137 TAF5-like RNA polymerase II, p300/CBP-associated factor 0.65
Tcea1 Mm.207263 BG081444 Transcription elongation factor A (SII) 1 0.65
c Calb1 Mm.277665 BG072229 Calbindin-28K 0.64 b
AW539369 0.63
BG087011 0.63
c Fabp7 Mm.3644 AK021271 Fatty acid binding protein 7, brain 0.63 b
BQ551801 0.59
Rhoa Mm.757 BG081880 Ras homolog gene family, member A 0.59
BQ551690 0.58
BG076236 0.58
c Sc4mol Mm.30119 BG083949 Sterol-C4-methyl oxidase-like 0.58 b
Mm.336117 BG081054 X-linked lymphocyte-regulated 3A 0.58
BG085378 0.57
c Itm2a Mm.193 BG088255 Integral membrane protein 2A 0.53 b
AW558689 0.42
c Gprasp1 Mm.271980 AW553322 G protein-coupled receptor associated sorting protein 1 0.25 b
c Mecp2 Mm.131408 BQ553027 Methyl CpG binding protein 2 0.05 b
Only probes with ,0.67-fold change are shown.
Genes selected for subsequent assays are in bold and indicated by arrows (c b).
doi:10.1371/journal.pone.0003669.t002
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shift in the histone modification pattern towards a more permissive
state of transcription [32].
Several expression profiles involving Mecp2-null samples have
been performed to date. Despite the different tissues and
specimens used, only small differences in expression patterns were
found. Two different approaches were adopted in studies of
human lymphocytes from RTT patients. First, the work of
Delgado et al. [33] avoided mosaicism by using lymphoid clones,
while, second, the study of Ballestar et al. [34] worked with non-
subcloned samples to approximate physiological conditions more
closely. In both cases, the decision to analyze lymphocytes was
useful, given that they are accessible and are not invasive for
patients. Another study used fibroblast strains from patients [35].
However, as RTT features seem to be caused mainly by a Mecp2
defect in the brain [23], it is possible that the peripheral
deregulation may not be equivalent to that happening in the
CNS and, unsurprisingly, these studies do not identify the same
deregulated genes as in the present work.
Nevertheless, the work performed with post-mortem RTT
brains [36] found a higher level of S100A9 expression, which is
consist with our results (Table 1). These data support our findings,
and it is possible that this study did not find more genes in
common because of the mosaicism of human samples, which could
have masked the subtle expression differences that we have
detected.
The study of Tudor et al. [19] was carried out with brain
samples in a different mouse model of RTT [23] and no genes
were found in common with ours, possibly due to their different
approach. Their work examined changes associated with disease
progression before and after the onset of RTT symptoms. As they
did not find any significant differences in expression they looked
for predictor genes that could classify their samples. Given that
their purpose and approach differed from ours, it is not surprising
that they obtained different results from us.
Finally, it is essential to compare our results with those from
studies performed in the same mouse model of RTT as
investigated here. We found Fkbp5 among the genes that are
regulated by Mecp2 through the techniques of the microarray,
qRT-PCR, ChIP, and BS. Given that Fkbp5 is already known to
be an upregulated gene in this RTT mouse model [27], it
represents a good control of the accuracy of all the experimental
assays. Moreover, a recent publication by Jordan et al. [31] showed
that Irak1 was more strongly expressed in cerebellum, but here we
show that this upregulation is common to all KO brain tissue.
However, there is some controversy regarding Gtl2. On one hand,
Kriaucionis et al. [37] detected higher Gtl2 levels in whole brain
samples from late symptomatic mice, but on the other, another
report [31] could not confirm differences in Gtl2 expression
between WT and KO in cerebellum or forebrain using qRT-PCR.
Our results clearly showed no difference in Gtl2 levels between any
brain regions in WT and KO mice. We found that Mecp2 binds
upstream of Gtl2 but we suggest that this affects Dlk1 expression
according to the regulation previously described for this region
[28,29].
The importance to RTT of the genes identified in our work
becomes evident from a detailed study of each of them
individually. First, three genes regulated by Mecp2 are imprinted,
a process in which Mecp2 had been already implicated [38,39].
One of those genes, Dlk1, is a paternally expressed gene that
encodes a protein homologous to the Notch/Delta family. Dlk1 is
active both as a soluble and a transmembrane protein, and plays
roles in the differentiation of several tissues [40–43]. In fact, a
recent study related its function with ventral midbrain-derived
dopaminergic precursor differentiation [44]. An intergenic
differentially methylated region located 13 kb upstream of Gtl2
regulates expression of the imprinted domain of murine distal
chromosome 12 [28,29]. Therefore, we verified that Mecp2 binds
the sequence responsible for Dlk1 expression without changing the
levels of Gtl2. Our study identified a new partner of the mechanism
involved in the regulation of imprinting of this region that may
also be involved in neuronal differentiation.
The other imprinted gene, Plagl1 (Zac1/ Lot1), is located in
human and mouse chromosomal regions that are maternally
imprinted [45,46], and seems to control cell fate during
neurogenesis, chondrogenesis, and myogenesis [47]. Nevertheless,
our results may indicate the existence of a more complex network,
given that Plagl1 acts as a transcription factor [48]. It has been
demonstrated that Plagl1 re-expression in a neuroblastoma cell line
induces several imprinted genes, including Dlk1 [49]. Consequent-
ly the upregulation of Dlk1 could be caused by a double pathway;
one involving the missing regulation of Mecp2, and the other
involving Plagl1.
Figure 1. Schematic strategy used to identify new Mecp2
target genes in a mouse model of RTT.
doi:10.1371/journal.pone.0003669.g001
Mecp2 Targets in Rett
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Figure 2. Relative expression results of each gene by qRT-PCR (normalized with respect to Gapdh). Genes confirmed to have significantly
different expression in Mecp2-WT and KO samples are shown. White bars correspond to WT samples and black bars to KO. Values for each tissue are
displayed separately. Data are from three independent biological replicates. Error bars indicate standard deviation (SD).
doi:10.1371/journal.pone.0003669.g002
Mecp2 Targets in Rett
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Other Mecp2-target genes are related to a wide spectrum of
functions. For instance, Mobp is one of a family of oligodendro-
cyte-specific polypeptides. Several Mobp features suggest a
possible key role in CNS biogenesis [50]. Intriguingly, however,
Mobp-null mice lack any clinical phenotype [51]. Further research
into this protein is required in order to identify its function and
mechanism of action, and thereby assess the relevance of its
upregulation to RTT pathology.
L-dopa decarboxylase (Ddc) is involved in the production of
monoamine neurotransmitters and it is the rate-limiting enzyme
for the synthesis of trace amines in mammals [52,53]. Although
Ddc activity is modulated by several factors [54–56], little is known
about its gene regulation. Moreover, this enzyme’s involvement in
the pathology of neoplastic, neurological, and psychiatric disorders
[57–59] may be related to RTT symptoms.
Mllt2h, also known as Af4, is a member of a family of four
proline- and serine-rich proteins whose conserved ALF domain is
thought to act as a transcriptional factor [60]. Detailed research
with the robotic mouse model has shown that the regulation of the
Af4 family is important for the normal function of the CNS [61].
Moreover, robotic mutant Af4 is deficiently degraded [61] and, as
a result, an increased amount of the protein interacts with its
Table 3. Significance (p-value) of Welch’s t test comparing relative expression values of WT vs. KO tissues from each gene.
UPREGULATED GENES
Cortex Midbrain Cerebellum
Fkbp5 0.0001 *** 0.0158 * 0.0015 **
Mt1 0.0535 0.1844 0.0939
Bai1 0.0299 * 0.1142 0.0903
Mt2 0.0776 0.0191 * 0.0778
Pcolce2 0.1591 0.0064 ** 0.0944
Irak1 0.0022 ** 0.0087 ** 0.0019 **
Mobp 0.0217 * 0.0378 * 0.0016 **
ProDH 0.0488 * 0.1732 0.0319 *
Dlk1 0.0017 ** 0.0469 * 0.0029 **
Plagl1 0.0022 ** 0.0148 * 0.0314 *
Ddc 0.0061 ** 0.0011 ** 0.0028 **
Gas5 0.8500 0.5158 0.0810
Mllt2h 0.0063 ** 0.0047 ** 0.0104 *
Txnip 0.0610 0.0380 * 0.2077
Eya2 0.0019 ** 0.0014 ** 0.0061 **
CPM 0.0693 0.1563 0.0502
Nudt9 0.2216 0.7973 0.8545
Pxmp2 0.3373 0.0474 * 0.1439
Ucp2 0.0632 0.6477 0.1687
S100a9 0.0256 * 0.0198 * 0.0728
Gtl2 0.5726 0.3441 0.3158
DOWNREGULATED GENES
Cortex Midbrain Cerebellum
MeCP2e1 0.0027 ** 0.0010 *** 0.0210 *
MeCP2e2 0.0023 ** 0.0009 *** 0.0119 *
Gprasp1 0.0323 * 0.0080 ** 0.0321 *
Itm2a 0.0185 * 0.0050 ** 0.0017 **
Sc4mol 0.0078 ** 0.0459 * 0.1178
Fabp7 0.0205 * 0.0743 0.0088 **
Calb1 0.0086 ** 0.3338 0.0405 *
Sst 0.0147 * 0.0148 * 0.0332 *
Oprk1 0.0981 0.0072 ** 0.0612
Gamt 0.0419 * 0.2831 0.2741
Creb1 0.0016 ** 0.0148 * 0.0258 *
Asterisks show the level of significance: * for p,0.05, ** for p,0.01, and *** for p,0.001.
Genes that appear in bold were consistently and significantly upregulated in at least two tissues and were selected for subsequent assays.
Among the down-regulated genes appear those ones selected from the article: Chahrour M, Jung SY, Shaw C, Zhou X, Wong ST, Qin J, Zoghbi HY (2008) MeCP2, a key
contributor to neurological disease, activates and represses transcription. Science 320:1224–1229.
doi:10.1371/journal.pone.0003669.t003
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targets. Our Mecp2-null mice model showed stronger Mllt2h (Af4)
expression; we propose that it could share characteristics with the
robotic mouse based on the large amount of Af4 present.
Obviously, further research is required to investigate this
hypothesis.
Mammalian Eya (Eyes Absent) proteins are predominantly
cytosolic proteins that interact with members of the Six family of
transcription factors. This interaction facilitates the translocation
of Eya into the nucleus, where it serves as a coactivator of Six in
the regulation of downstream genes [63] controlling precursor cell
proliferation and survival during mammalian organogenesis [64].
However, Eya2 also binds selectively to some forms of active
heterotrimeric Gai proteins, preventing its translocation into the
nucleus and avoiding Eya2/Six4-mediated transcription [65]. All
these phenomena require careful exploration in order to
determine thoroughly their possible involvement in brain
development and in RTT.
S100 proteins are the largest family within the EF-hand protein
superfamily. They are small acidic proteins exclusive to vertebrates
that display some unique features not present in other EF-hand
proteins [66]. Moreover, the heterodimers of S100A8 and S100A9
are the main calcium-binding proteins in phagocytes, where they
regulate migration-modulating tubulin polymerization [67]. Nev-
ertheless, complex, extracellular regulatory activities of the
S100A8/S100A9 heterodimer, and, possibly, different functions
of individual S100A9 and S100A8 homodimers have been
suggested [68]. In any case, calcium is a ubiquitous second
messenger that regulates a wide range of cellular events. Different
calcium signals would lead to cellular changes involving calcium-
binding proteins such as the S100 family. The effects of the
overexpression of S100a9 in RTT pathology require further
analysis.
Finally, two genes were upregulated due to an indirect
mechanism caused by the lack of Mecp2. The first one, Irak1 is
located downstream of Mecp2 in mouse (X29.6cM) and human
(Xq28). Its overexpression may be due to a negative regulator loss
or a chromatin structure abnormality caused by the deletion
produced by knocking out Mecp2. This is currently the most
plausible explanation, given that other RTT mouse models have
been analyzed but not have not shown Irak1 deregulation.
However, large deletions of MECP2 including IRAK1 have already
been reported in RTT patients [69]. A more profound study of
Figure 3. Results from chromatin immunoprecipitation assays.
For Mecp2-WT and KO animals a fraction of total DNA (Input), a no-
antibody control (NAB), and a fraction immunoprecipitated by the
antibody (Mecp2 B) were tested. Three replicates of each reaction were
performed.
doi:10.1371/journal.pone.0003669.g003
Figure 4. Plots representing bisulfite genomic sequencing
results for the 59-regions of the upregulated genes identified in
Mecp2 null mice. Each shows a cloned fragment and the CpGs
included. Ten clones are shown for every gene in which one column
represents a CpG. Given that no differences were found between
tissues or samples, one representative sample is shown for each gene.
White squares correspond to non-methylated CpGs and black squares
to methylated CpGs.
doi:10.1371/journal.pone.0003669.g004
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their relationship could lead to a better understanding of the
chromatin regulation of this region and might explain some
features of the disease. The second gene, Prodh, encodes proline
oxidase (POX), a mitochondrial inner-membrane flavoenzyme
that is expressed in brain, liver, and kidney. This enzyme catalyzes
the rate-limiting step of proline degradation [70]. This reaction,
apart from being related to glutamate and ornithine synthesis, can
transfer redox potential between subcellular compartments and
between cells [71,72]. Furthermore, proline protects against
oxidative stress, and overexpression of POX results in decreased
cell survival [73]. Several studies of Prodh deficiency have
associated mutations in its gene with cognitive defects, autistic
behavior and epilepsy [74–76], which underlines its importance in
proper brain function. Additionally, proline metabolic properties
in the CNS suggest that this aminoacid can act as an inhibitory
neurotransmitter and/or as a metabolic precursor of glutamate in
subpopulations of glutamatergic neurons [71,72,77]. For these
reasons we hypothesize that Prodh overexpression and its
corresponding increased catalytic activity could lead to a condition
of neurotransmitter imbalance in the brain that might be
accompanied by reduced cell survival.
In summary, all the genes reported in our study are of use to us
for gaining a better understanding of the development and
progression of RTT. The diversity of the pathways involved attest
to the great complexity of this disease. Further studies are
necessary to extend our knowledge of the deregulated network of
genes and affected mechanisms that are involved in RTT.
Materials and Methods
Animal model
B6.129P2(C)-Mecp2tm1.1Bird/J (stock number: 003890) heterozy-
gous females (Mecp2+/2) and wild-type females were obtained from
the Jackson Laboratory (Bar Harbor, ME). Briefly, the mutant
strain was generated by replacement of exons 3 and 4 of Mecp2 in
embryonic stem cells with the same exons flanked by loxP sites.
The deletion of the gene was achieved by crossing Mecp2lox/lox
females with mice with ubiquitous Cre expression [24]. Mecp2+/2
females were mated with C57BL/6J males and their offspring
were genotyped by PCR according to the supplier’s protocol
(http://jaxmice.jax.org/strain/003890_3.html).
Mouse housing and sample collection
Animals were kept under specific pathogen-free conditions in
accordance with the recommendations of the Federation of
European Laboratory Animal Science Associations. Mice were
inspected daily and maintained under controlled lighting condi-
tions (lights on from 08:00h to 18:00h), at constant temperature
(22uC), and were allowed ad libitum access to food and water.
All experiments were performed in hemizygous Mecp2-null
males (Mecp22/y) aged 6–10 weeks. Mice were euthanized in
accordance with the Guidelines for Humane Endpoints for
Animals Used in Biomedical Research. Samples were obtained
from KO mice and their WT littermates after the establishment of
RTT symptoms in the defective animals. Brains were removed
and divided into cortex, midbrain, and cerebellum. The brain
regions were dissected, immediately frozen on dry ice, and stored
at 280uC until use, except for tissue used ChIP assay samples,
which was freshly processed. WT and KO mouse tissues were
extracted and handled under identical conditions.
RNA isolation, amplification, and hybridization
Tissue samples were homogenized in Trizol reagent (Invitrogen
Corp., Carlsbad, CA). Phase separation was done following the
manufacturer’s instructions (http://www.invitrogen.com/con-
tent/sfs/manuals/15596026.pdf). RNA was preferentially purified
using the RNeasy Mini kit (Qiagen Inc., Valencia, CA). RNA was
cleaned up by RNase-free DNase I treatment (Qiagen Inc.). Total
RNA was quantified by spectrophotometry and quality was
verified on an agarose gel.
For amplification, 4 mg of total RNA were first reverse-
transcribed using T7-oligo (dT) promoter primer, followed by
RNase-H-mediated second-stranded cDNA synthesis (Invitrogen
Corp.). Double-stranded cDNA was purified and served as a
template in the subsequent RNA polymerase amplification
(MEGAscript T7, Ambion Inc., Austin, TX). Amplified RNA
was purified using RNeasy Mini kit (Qiagen Inc.), then quantified
and its quality confirmed as for the total RNA.
Amplified RNA was reverse-transcribed and labeled using
random hexamers (Promega) and Cy3 or Cy5-dUTP (Amersham,
Piscataway, NY), depending on the sample (control or Mecp2-null
tissue, respectively). After degradation of template RNA, every
labeled sample was purified using the Cyscribe GFX Purification
kit (Amersham). Samples for comparison were mixed in pairs in
order to carry out a direct competition hybridization experiment,
then combined with SlideHyb Buffer (Ambion), mouse Cot-1
DNA (Invitrogen Corp.), RNA polyA (Sigma-Aldrich, St Louis,
MO), and yeast tRNA (Invitrogen Corp.). Samples were
subsequently hybridized to CNIO mouse cDNA microarrays.
Microarray analysis
Briefly, the CNIO mouse cDNA microarray contains both the
NIA 15 K and 7.4 K clone sets from the National Institute on
Aging (http://lgsun.grc.nia.nih.gov/cDNA/cDNA.html), and an
additional 600 clones specifically associated with cancer, angio-
genesis, apoptosis, signal transduction, and stress processes as well
as control probes. A total of 12 array hybridizations were
performed, consisting of four biological replicates of the three
different brain regions. After washing, slides were scanned for Cy3
and Cy5 fluorescence using Scanarray 5000 XL (GSI Lumonics,
Kanata, Ontario, Canada), and quantified using GenePix Pro 4.0
software (Axon Instruments Inc., Union City, CA). Data were
processed as described previously [34], and the results were
expressed as the relative change (KO/WT). Genes were
considered to be upregulated or downregulated if the ratio was
at greater than 1.5 or less than 0.67, respectively. The microarray
expression data could be studied from the NCBI-GEO, database
entry GSE11596 (http://www.ncbi.nlm.nih.gov/geo/query/acc.
cgi?acc =GSE11596).
Quantitative real-time reverse transcriptase polymerase
chain reaction (qRT-PCR)
Total RNA (1 mg) was reverse-transcribed using random
primers with SuperScriptTM II reverse transcriptase (Invitrogen
Corp.). A negative control reaction was run to confirm the absence
of genomic DNA contamination. Furthermore reverse transcrip-
tion-PCR primers were designed between different exons to avoid
any amplification of genomic DNA. In order to establish the most
appropriate conditions for the reaction the quantity of sample
template was tested. As a result, 25 ng of cDNA were used for
each PCR amplification.
The quantitative real-time PCRs [79] were set up in a reaction
volume of 20 ml. Each reaction mixture contained 9 ml of the
experimental cDNA, 500 nM of each primer, and 10 ml of 26
SYBR Green PCR Master Mix (Applied Biosystems, Foster City,
CA). Multiple negative water blanks were tested, and a calibration
curve was determined in parallel with each analysis. All
measurements were performed in triplicate and three biological
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replicates of the experiment were tested. Expression values were
normalized with respect to Gapdh expression as an endogenous
control. PCR reactions were run and analyzed using the 7900HT
Sequence Detection System (Applied Biosystems) under the
thermal cycling conditions recommended by the manufacturer.
qRT-PCR was carried out in WT and KO samples from all brain
tissues to quantify the following mouse genes: Fkbp5, Mt1, Bai1,
Mt2, Pcolce2, Irak1, Mobp, Prodh, Dlk1, Plagl1, Ddc, Gas5, Mllt2h,
Txnip, Eya2, Cpm, Nudt9, Pxmp2, Ucp2, S100a9, Gtl2, Gprasp1,
Mecp2e1, and Mecp2e2. Primer sequences (Sigma-Aldrich, St Louis,
MO) are listed in Supplementary Table 1.
To determine whether the expression of genes was significantly
different between groups we applied Welch’s t test [80], which
takes into account unequal variances. In this particular case we
compared WT and KO mice values for all the genes studied in
each tissue separately.
Chromatin immunoprecipitation
The parts of the brain from WT and KO mice were separately
chopped into small pieces and incubated at 37uC for 1.5 hours in
Hank’s balanced salt solution (HBSS) with collagenase (300 U/
ml). Homogenized tissues were washed twice in cold phosphate-
buffered saline (PBS) containing protease inhibitors (cOmplete
EDTA-free, Roche Diagnostics, Indianapolis, IN). For preparation
of crosslinked chromatin, they were incubated in PBS with 1%
formaldehyde for 15 min at RT. Crosslinking was stopped by
adding glycine to 125 mM, and cells were washed in PBS. All
subsequent procedures were performed on ice, with buffers
containing the protease inhibitors (cOmplete EDTA-free) as
previously described [21]. Sonication yielded chromatin fragments
of 300–600 bp in length. Immunoprecipitations were performed
using 5 mg of a rabbit polyclonal anti-MeCP2 [81]. The sensitivity
of PCR amplification was tested using serial dilutions of total DNA
collected after sonication (input fraction), and three independent
experiments were performed for each analyzed promoter. The
samples used for PCR amplification included total DNA (‘‘Input’’),
a washing fraction of the no-antibody control (‘‘NAB’’), and the
fraction immunoprecipitated by the antibody (Bound: ‘‘Mecp2
B’’). We included an immunoprecipitation for total histone H3 to
show that the chromatin purified from the KO animals was
prepared exactly as that from wild-type animals. We also included
a negative control IgG antiserum to show that the obtained signals
were not due to a specific association of the Mecp2 antiserum to
certain chromatin structures. After PCR, all products were run in
a 2% agarose gel. Quantitative real-time PCR analysis was
performed on an ABI 7900HT sequence detection system (Applied
Biosystems, Foster City, CA) using SYBRH Green. The quanti-
tative real-time PCR data were analyzed as described by
Chahrour et al. (22). Primer sequences are listed in Supplementary
Table 1.
Bisulfite genomic sequencing
Genomic DNA was extracted from each mouse brain region,
and bisulfite modification was carried out as previously described
[82]. Primers for PCR amplification of the bisulfite-modified DNA
were designed with Methyl Primer ExpressH Software (www.
appliedbiosystems.com/methylprimerexpress), which ensures
primer specificity for bisulfite-converted DNA and avoids CpGs
in their sequence. PCR amplicons were purified with Ultra Clean
GelSpin kit (MO BIO Laboratories, Inc.). PCR products were
subcloned into the pGEM-T Easy Vector (Promega), and clones
were picked in 96-well plates for sequencing (Montage Plasmid96
Miniprep Kit, Millipore). After a hot start (96uC for 1 min) and
thermocycling (30 cycles of 96uC for 5 s, 50uC for 5 s, and 55uC
for 4 min) using a BigDye Terminator V3.1 Cycle Sequencing Kit
(Applied Biosystems), samples were purified using PERFORMA
V3 96-Well Short Plate (EdgeBioSystems) apparatus, and then
sequenced using a 31306l Genetic Analyzer (Applied Biosystems).
CpG methylation status was determined for all gene promoters
separately for the three different brain regions of WT and KO
mice. Ten clones were analyzed from each of the six tissue
combinations. Primer sequences are listed in Supplementary
Table 1.
We carried out an ANOVA to examine possible effects of
genetic condition of mice (WT vs. KO). Since the data are
proportions, we used the standard [83] transformation arc-
sin(sqrt(p)), where p is the percentage methylation. We first
modeled the proportion of methylation as a function of the genetic
condition of mice, gene (since there could be differences in
methylation related simply to being one gene or other), tissue (to
account for any differences in methylation related to tissue), and
two interactions – the gene6genetic condition (i.e., KO and WT
might have different effects on methylation depending on the gene
on which they were acting) and gene6tissue. In the eventm the
type II sums of squares [84] indicated no evidence of significant
interactions (gene6gene condition, p = 0.99; gene6tissue,
p = 0.688), so these terms were dropped, to give a final model
containing only the three main effects. Analyses were done using R
[85] and the car library [86].
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